Please login to the form below

Not currently logged in
Email:
Password:

evacetrapib

This page shows the latest evacetrapib news and features for those working in and with pharma, biotech and healthcare.

CETP inhibitor class finally dies as Merck abandons anacetrapib

CETP inhibitor class finally dies as Merck abandons anacetrapib

The drug follows in the footsteps of other CETP inhibitors - including Pfizer's torcetrapib, Roche's dalcetrapib and Eli Lilly's evacetrapib - although those candidates all failed to show a benefit

Latest news

More from news
Approximately 2 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Pharma deals in September 2015 Pharma deals in September 2015

    Whilst Roche and Pfizer failed to overcome efficacy and safety concerns regarding their candidates, Eli Lilly's (evacetrapib) and Merck's (anacetrapib), products are looking to raise HDL levels and these

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics